ARCH Venture Fund XIII Makes Substantial $12.5M Open Market Purchase, Part of Coordinated $25M Insider Buy
LYEL has more than doubled off its 52-week low of $7.65 on elevated volume (2.1× avg).
Summary
ARCH Venture Fund XIII and its affiliates, all 10% owners, made a substantial $12.5 million open market purchase of Lyell Immunopharma shares, part of a larger, coordinated $25 million insider buying effort by the ARCH group.
Key Events · Ownership and Investor Activity · LYEL
-
Significant Insider Purchase
ARCH Venture Fund XIII, L.P. and its affiliated 10% owners acquired 488,090 shares of Lyell Immunopharma common stock in an open market purchase valued at $12,499,985 on March 6, 2026.
-
Substantial Investment Relative to Market Cap
This single transaction represents approximately 2.3% of Lyell Immunopharma's current market capitalization, indicating a high-conviction investment.
-
Coordinated Institutional Buying
This purchase is part of a larger, coordinated effort by the ARCH Venture group, with another affiliated fund (ARCH Venture Fund IX) reporting a similar $12.5 million purchase on the same day, bringing the total insider buying from this group to approximately $25 million.
-
Strong Accumulation Signal
The combined insider buying from the ARCH group on this day amounts to roughly 4.6% of the company's market cap, reinforcing a strong accumulation trend by key institutional investors.
Analysis · LYEL · Life Sciences
This Form 4 reports a significant open market purchase of Lyell Immunopharma shares by ARCH Venture Fund XIII, L.P. and its affiliated 10% owners, totaling nearly $12.5 million. This transaction, representing over 2.3% of the company's market capitalization, signals strong conviction from a major institutional investor. Notably, this filing explicitly states it is one of two reports related to a joint transaction, with another ARCH Venture Fund (ARCH Venture Fund IX) also reporting a similar $12.5 million purchase on the same day. The combined $25 million investment from the ARCH group, representing approximately 4.6% of the company's market cap, indicates a highly bullish stance and a substantial vote of confidence in Lyell Immunopharma's future.
At the time of this filing, LYEL was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $541.7M. The 52-week trading range was $7.65 to $45.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.